The strong revenue growth and lucrative margins of Illumina's (ILMN)
core sequencing business has attracted ample competition over the
years. It's testament to the quality of Illumina's technology (both
acquired and internally-developed), though that a lot of these
competitive attempts have only served to highlight the attributes and
advantages of the company's approach.
I certainly have my
questions and doubts about Illumina. I do think the company was caught a
little flat-footed by the success of Life Technologies' (LIFE)
Ion Torrent products, and my talks with several people in
academic/research labs do lead me to believe they rushed their
high-throughput products to market (leading to some unhappy customers).
Last and not least, I think that Street expectations for
sequencing-driven clinical diagnostics could be ambitious. All of that
said, though, it's hard not to acknowledge and appreciate the business
that Illumina is building here.
Please follow this link to continue:
Illumina Flexes Its Muscles A Bit
No comments:
Post a Comment